| Ticker: DITI | Nine Delta Drive | |
| Exchange: NASDAQ-National Market | Londonberry, New Hampshire 03053 | |
| Industry: Manufacturing | (603) 437-8970 |
| Type of Shares: | Common Shares | Filing Date: | 4/10/96 | |
| U.S. Shares: | 2,200,000 | Offer Date: | 6/13/96 | |
| Non-U.S. Shares: | 0 | Filing Range: | $10.00 - $12.00 | |
| Primary Shares: | 2,200,000 | Offer Price: | $8.50 | |
| Secondary Shares: | 0 | Gross Spread: | $0.60 | |
| Offering Amount: | $24,200,000 | Selling: | $0.35 | |
| Expenses: | $800,000 | Reallowance: | $0.10 | |
| Shares Out After: | 10,205,255 |
| Manager | Tier | Phone |
| Dillon, Read & Co. Inc. | Lead Manager | (212) 906-7000 |
| Oppenheimer & Company, Inc. | Co-manager | (212) 667-7402 |
| Auditor: Ernst & Young | |||||
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/95 | 3/31/96 | 3/31/95 | 3/31/96 | ||
| Revenue: | $1.52 | $0.50 | $0.00 | Assets: | $8.55 |
| Net Income: | -$6.41 | -$2.36 | $1.51 | Liabilities: | $1.54 |
| EPS: | -$0.90 | -$0.29 | Equity: | $7.01 | |
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company is engaged in the discovery and development of proprietary radio pharmaceuticals for use in nuclear medicine imaging products. The company is applying its proprietary peptide and radiolabelling technologies to the development of technetium-99m labelled synthetic peptides as medical imaging agents for life-threatening and chronic diseases and conditions. Because Techtides are designed to bind selectively with molecular targets that localize or proliferate to product images based on the process of disease rather than the anatomical result of disease, which may alter patient treatment protocols. The company believes that its Techtides will permit a number of clinically important new diagnostic procedures to be performed using the large installed base of nuclear medicine imaging equipment and that nuclear medicine imaging with Techtides may be more accurate, more cost-effective, less invasive and/or safer than alternative imaging modalities for certain diseases and conditions. |
| Use of Proceeds |
| The proceeds from the offering will be used to fund research and development, including applications and preclinical trials, repayment of bank debt, for general corporate purposes, including satisfactory capital requirements. |
©1996 IPO Data Systems, Inc. - All rights reserved.